苏黄止咳胶囊治疗呼吸系统疾病临床应用专家共识  

Expert consensus on clinical application of Suhuang Zhike Capsules in treatment of respiratory diseases

作　　者：明雨 黄常芮 俞邦 常文婧 孙增涛[4] 陈薇[3] 张洪春[5] MING Yu;HUANG Chang-rui;YU Bang;CHANG Wen-jing;SUN Zeng-tao;CHEN Wei;ZHANG Hong-chun(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Beijing University of Chinese Medicine,Bejing 100029,China;Center for Evidence-based Medicine,Beijing University of Chinese Medicine,Bejing 100029,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Center of Respiratory Medicine,Department of Traditional Chinese Medicine for Pulmonary Diseases,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700 [2]北京中医药大学,北京100029 [3]北京中医药大学循证医学中心,北京100029 [4]天津中医药大学,天津301617 [5]中日友好医院呼吸中心中医肺病科,北京100029

出　　处：《中国中药杂志》2025年第3期817-823,共7页China Journal of Chinese Materia Medica

基　　金：国家中医药管理局2022年全国名老中医药专家(张洪春)传承工作室建设项目(国中医药人教函[2022]75号)。

摘　　要：临床上苏黄止咳胶囊广泛用于呼吸系统疾病的治疗,已纳入《国家基本医疗保险、工伤保险和生育保险药品目录》《国家基本药物目录》,但在实际应用中仍存在疗程界定不清、禁忌人群不明等问题。因此,该共识由中医肺系病、呼吸及危重症医学领域的临床、方法学和药学专家共同制订,严格遵循中华中医药学会中成药临床应用专家共识步骤进行研制,以期指导临床正确使用苏黄止咳胶囊治疗咳嗽变异性哮喘、感冒后咳嗽和其他呼吸系统疾病。共识采用问卷调查、专家访谈的形式,根据PICOS原则确定临床关注问题,并进行证据评价和GRADE系统分级,采用名义组法和GRADE网格化方法产生推荐意见和共识建议,最终形成17条推荐意见和共识建议。该共识进一步明确了苏黄止咳胶囊治疗咳嗽变异性哮喘和感冒后咳嗽的适应证、中医证候、用法用量等,说明其临床安全性,旨在推进规范用药,促进苏黄止咳胶囊的临床合理应用。Suhuang Zhike Capsules are widely used in clinical practice for the treatment of respiratory diseases and have been included in Medicine Catalogue for National Basic Medical Insurance,Work Injury Insurance,and Maternity Insurance and National Essential Medicines List.However,problems remain,such as unclear definitions of treatment courses and unidentified contraindications for certain populations.Therefore,this consensus was developed collaboratively by clinical experts in traditional Chinese medicine(TCM)related to pulmonary diseases,respiratory,and critical care medicine,as well as methodology and pharmacy experts,adhering strictly to the consensus development procedures established by the China Association of Chinese Medicine for clinical application of Chinese patent medicines,with the aim to guide the correct clinical use of Suhuang Zhike Capsules for the treatment of cough variant asthma,post-infectious cough,and other respiratory diseases.This consensus employed questionnaire surveys and expert interviews to identify clinical concerns based on the PICOS principle and conduct evidence evaluation and GRADE grading.Utilizing nominal group techniques and GRADE networking methods,it resulted in 17 recommendations and consensus suggestions.The consensus further clarifies the indications,TCM syndromes,usage,and clinical safety of Suhuang Zhike Capsules in the treatment of cough variant asthma and post-infectious cough,aiming to promote standardized medication use and facilitate the rational clinical application of Suhuang Zhike Capsules.

关 键 词：苏黄止咳胶囊 咳嗽变异性哮喘 感冒后咳嗽 专家共识 GRADE 

分 类 号：R259[医药卫生—中西医结合]